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Purpose: Efficacy, tolerability and safety of the novel preservative-free prostaglandin tafluprost 
0.0015% were investigated for the treatment of patients with glaucoma or ocular hypertension 
in a clinical setting.
Patients and methods: Data were collected in a non-interventional, prospective, multi-center, 
observational, open label study. 118 patients were treated with a prostaglandin analog (PGA) 
monotherapy (preserved formulations of latanoprost, travoprost or bimatoprost) prior to baseline. 
Intraocular pressure (IOP) readings were recorded for each eye at baseline   (previous therapy), 
4–6 weeks, and 12 weeks after changing medical treatment to preservative-free   tafluprost 
once-daily. We analyzed the change in IOP over the study period for all patients as well as for a 
subgroup of patients with prior PGA monotherapy. Subjective symptoms and objective ocular 
signs were determined. Comfort was measured using a 4 step scale. All adverse events were 
recorded. Paired t-tests were conducted to compare IOP values at baseline to IOP values after 
treatment with tafluprost 0.0015%. Bowker’s test of symmetry was used for statistical evaluation 
of changes of clinical signs (hyperemia).
Results: In total 118 patients were eligible for evaluation. In these patients with prior PGA 
monotherapy (n = 118) IOP decreased significantly from 16.2 ± 4.3 mm Hg (95% CI: 0.55) 
at treated baseline to 14.8 ± 3.2 mm Hg (95% CI: 0.43; P , 0.001) at final visit on tafluprost. 
In a subset of patients with prior latanoprost monotherapy (n = 68) mean IOP at baseline 
(±SD) was reduced from 16.2 ± 4.6 mm Hg (95% CI: 0.77) 14.8 ± 3.1 mm Hg at final visit 
(95% CI: 0.54, P , 0.001), in patients with prior travoprost monotherapy (n = 32) from 
16.2 ± 4.3 mm Hg (95% CI: 1.05) to 14.9 ± 3.3 mm Hg (95% CI: 0.91; P , 0.05) and in 
patients with prior bimatoprost monotherapy (n = 18) from 16.4 ± 3.5 mm Hg (95% CI: 1.14) 
to 15.0 ± 3.3 mm Hg (95% CI: 1.14; P = 0.252). Both, objective clinical signs and subjective 
symptoms improved after changing medication to preservative-free tafluprost until final visit. 
The number of patients with moderate and severe hyperemia decreased from 51 (43.2%) at 
baseline to 2 (1.9%) at final visit.
Conclusion: Preservative-free tafluprost 0.0015% was effective, well tolerated and safe. IOP 
was controlled effectively and ocular symptoms and clinical signs were improved after chang-
ing medication to a monotherapy with preservative-free tafluprost in patients previously treated 
with a preserved latanoprost, travoprost or bimatoprost monotherapy.
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Introduction
Glaucoma is the second leading cause of preventable blindness worldwide. In 2010 
worldwide approximately 60.5 million people are suffering primary open angle Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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glaucoma (POAG) and angle closure glaucoma (ACG). This 
number is estimated to increase to 79.6 million by 2020.1 
Increased intraocular pressure (IOP) is   considered to be the 
most important but modifiable risk factor.2–4   Worldwide, 
prostaglandin analogs (PGAs) have become the major thera-
peutic class for medical treatment of glaucoma because of 
their efficacy and generally well tolerated systemic safety 
profile.5 Tafluprost is a novel PGA that has been approved 
for ophthalmic use in a number of markets worldwide. The 
drug is currently marketed under the brand names: Taflotan+ 
and Taflotan+ sine and Tapros†, by Santen Pharmaceutical Co. 
LTD, Japan and as Saflutan†† by Merck & Co , Inc.   Tafluprost 
is highly selective for the prostaglandin FP-receptor.6,7 
PGAs including Tafluprost have a strong, sustained and 
stable IOP-lowering effect with few systemic side effects. 
In clinical studies the drug lowered IOP effectively and was 
generally well tolerated.8–10 Unfortunately, PGAs may induce 
local adverse events, including conjunctival hyperemia, iris 
and periocular skin pigmentation and eyelash growth.9,11 
Hyperemia is the most common local adverse reaction to 
PGAs. Furthermore this local adverse event seems to be 
dose-dependent.12,13 Tafluprost is commercially available in a 
low concentration of the active ingredient of 0.0015%. Fur-
thermore, among all widely used PGAs, tafluprost is the first 
and only preparation that is available in a preservative-free 
formulation. This may be important because special attention 
has been paid to the cytotoxicity of benzalkonium chloride 
(BAK), which is widely used in glaucoma preparations as a 
preservative. BAK is pro-apoptotic, pro-inflammatory and 
causes a damage of the tear film by emulsification of the lipid 
layer.14–16 A complete loss of conjunctival goblet cells was 
also reported in different studies.17,18 Other clinical studies 
demonstrate major differences with respect to subjective 
symptoms, local tolerability and objective clinical signs 
after the use of preserved and preservative-free glaucoma 
medications.19–21
The overall results of this observational study have 
already been published.22 The purpose of this post-hoc 
analysis was to assess efficacy, tolerability and safety of 
preservative-free tafluprost in a subset of patients that were 
switched from a prior monotherapy with preserved PGAs to 
a monotherapy with preservative-free tafluprost 0.0015% in 
a routine clinical setting.
Material and methods
study design
This was a non-interventional, observational, open-label, non-
randomized multi-center study, that was conducted between 
October 2008 and April 2009 in 75 centers in Germany. The 
study treatment was based on the decision of the physician 
only, regardless of study participation and   treatment use. 
German law does not require informed consent for this type 
of non-interventional observational study. Patients previ-
ously diagnosed with glaucoma or ocular hypertension who 
required a change of medication, an add-on therapy or who 
were naïve to medical treatment were followed for 12 weeks 
after changing medication to, or initiation of medical therapy 
with, the preservative-free formulation of tafluprost 0.0015% 
once-daily. The primary objective of this study was to evaluate 
the change of mean IOP from baseline to final visit. Secondary 
objectives were to evaluate the change of clinical signs and 
subjective symptoms from baseline to final visit.
Patients
The study included patients with different types of glaucoma 
and ocular hypertension, primarily those with tolerability issues 
and insufficient IOP control with prior medical therapy.
Measurements and statistical analysis
Using an internet- based standardized data collection format, 
participating ophthalmologists provided anonymous patient 
data. The switch was done at the physician’s discretion, and 
their reasons for recommending the new medication were 
collected by providing multiple categories (ocular signs and 
symptoms, lowering of IOP not sufficient, contraindication, 
systemic intolerability, progression of glaucomatous defects, 
tachyphylaxis, others). Demographics, information about 
prior treatments and IOP readings were recorded. Due to 
the observational character of the study no instructions were 
made to the study participants concerning the time of IOP 
measurements during the day and the time-point to administer 
the medication during the day (evening or   morning dose). 
The presence of subjective symptoms   (burning, foreign body 
sensation, itching, irritation, stinging, tearing, dryness) and 
clinical signs (hyperemia, corneal staining, blepharitis) were 
recorded subjectively by the physician using a 4-point scale 
(none, mild, moderate, severe) at the initial visit. Symptoms at 
final visit (week 12) were compared to baseline by the patient, 
and clinical signs were recorded by the physician. IOP mea-
surements were made using Goldman applanation tonometry 
for each eye, at the slitlamp in a sitting position, at baseline 
(run-in on prior treatment or start of medical   therapy), 4 to 
+ Taflotan®, Taflotan® sine,
† Tapros™ are registered trademarks of Santen Pharmaceutical Co., Ltd, 
Osaka, Japan. 
†† Saflutan® is a registered trademarks of Merck & Co., Inc.Clinical Ophthalmology 2011:5
Table 1 Patient demographics, diagnoses and medical treatment 
at baseline (n = 118)
Age (mean [range]) (years) 63.6 [32–92]
gender (male/female) 36/82
Diagnoses
– Ocular hypertension 14 (11.9%)
– Primary open angle glaucoma 93 (78.8%)
– normal tension glaucoma 10 (8.5%)
– exfoliative glaucoma 1 (0.8%)
glaucoma since years (mean [range]) 6.7 [1–22]
Prior PgA treatment (monotherapy)
– Latanoprost 68 (57.6%)
– Travoprost 32 (27.1%)
– Bimatoprost 18 (15.3%)
Abbreviation: PgA, prostaglandin analog.
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6 weeks and 12 weeks after changing treatment to preser-
vative-free tafluprost 0.0015%.   Glaucomatous damage was 
defined by using automatic perimetry, ophthalmoscopy and/
or optic nerve head/fundus imaging techniques. Paired t-tests 
were conducted to compare IOP values at baseline to IOP 
values after treatment with tafluprost 0.0015%. Bowker’s test 
of symmetry was used for statistical evaluation of changes 
of clinical signs (hyperemia). All adverse reactions were 
recorded by the physicians.
Results
Patient demographics and prior therapy
In 118 patients, medical treatment was changed from a prior 
PGA monotherapy at baseline to preservative-free   tafluprost 
0.0015%. The results from this subset of patients are reported 
here. The majority of patients in the PGA-subgroup were female 
(n = 82; 69.5%). Primary open angle glaucoma (POAG) was 
the most common diagnosis (n = 93; 78.8%) followed by ocular 
hypertension (OH) (n = 14; 11.9%), normal tension glaucoma 
(NTG) (n = 10; 8.5%) and exfoliative glaucoma (PEX) (n = 1; 
0.8%). At baseline prior to change of medication to a monother-
apy with preservative-free   tafluprost, 68 patients (57.6%) were 
treated with latanoprost, 32 patients (27.1%) with travoprost 
and 18 patients (15.3%) with bimatoprost (Table 1).
reasons for changing medication
Subjective symptoms and clinical signs were the most impor-
tant reasons for changing medical therapy (n = 72 patients; 
61.0%). Prior medication was changed for 24 patients 
(20.3%) due to efficacy reasons (Figure 1).
effect on iOP
Overall mean IOP (±SD) was 16.2 ±  4.3  mm  Hg 
(95% CI: 0.55) at treated baseline. Four to 6 weeks after 
changing   medication, overall mean IOP was reduced to 
15.0 ± 3.2 mm Hg (95% CI: 0.43), and after 12 weeks to 
14.8 ± 3.2 mm Hg (95% CI: 0.43) (Figure 2). This IOP 
reduction is   equivalent to 8.4% and 8.6% from treated 
baseline,   respectively. At both 4 to 6 weeks and 12 weeks, 
overall treated IOP values were significantly lower than 
baseline values (P , 0.001). A reduction of mean IOP was 
also achieved for all different PGA compounds: In patients 
with prior latanoprost monotherapy (n = 68) mean IOP at 
baseline (±SD) was reduced from 16.2 ± 4.6 mm Hg (95% 
CI: 0.77) to 14.8 ± 3.1 mm Hg at final visit (95% CI: 0.54; 
P , 0.001); in patients with prior travoprost mono-
therapy (n = 32) from 16.2 ± 4.3 mm Hg (95% CI: 1.05) 
to 14.9 ± 3.3 mm Hg (95% CI: 0.91; P , 0.05); and in 
patients with prior bimatoprost monotherapy (n = 18) from 
16.4 ± 3.5 mm Hg (95% CI: 1.14) to 15.0 ± 3.3 mm Hg 
(95% CI: 1.14; P = 0.252). In all patients with prior PGA 
monotherapy, IOP at final visit compared to baseline IOP 
was lower in 109 eyes (46.2%), equal in 51 eyes (21.6%) and 
higher in 76 eyes (32.2%) (Figure 3). In all patients with prior 
PGA monotherapy, preservative-free tafluprost 0.0015% 
provided IOP-values of #18 mm Hg for 83.1%, #16 mm 
Hg for 68.6%, #14 mm Hg for 51.7% and #12 mm Hg for 
28.0% of all eyes. In the subset of patients (n = 24) who were 
switched from prior PGA monotherapy to preservative-free 
tafluprost due to efficacy reasons mean IOP was lowered sig-
nificantly by -3.9 mm Hg (P , 0.001) compared to baseline. 
Individual IOP’s in those patients were lower at final visit 
compared to baseline in 28 eyes (58.2%), stayed the same 
in 12 eyes (25.0%) and were higher compared to baseline 
in 6 eyes (16.7%). In contrast IOP in two subsets of patients 
switched due to ocular signs (n = 31) and due to subjective 
symptoms (n = 41) a smaller effect on IOP reduction was 
observed (Table 2).
Clinical signs and ocular symptoms
Clinical signs also improved by the final examination 
(12 weeks after changing medical treatment). The fre-
quency and severity of hyperemia was reduced over the 
3 month treatment period. In all patients with prior PGA 
monotherapy the percentage of patients without any signs 
of hyperemia increased from 35.6% (n = 42) at baseline 
prior to changing medication to 87.7% (n = 93) (P , 
0.001). In addition, no severe hyperemia was observed 
at final visit 12 weeks after changing medication to 
preservative-free tafluprost   (Figure 4). At baseline prior 
to change of medication, burning, foreign body sensa-
tion, itching, irritation, stinging, tearing and dryness Clinical Ophthalmology 2011:5
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were reported by 55.9%, 36.5%, 33.1%, 58.5%, 16.9%, 
27.1% and 21.2% of patients respectively. These subjective 
symptoms improved by the final examination compared 
to baseline (Figure 5).
safety and terminations of treatment
Few adverse reactions were associated with the use of 
preservative-free tafluprost. One hundred and six patients 
completed the study and continued with a monotherapy 
with preservative-free tafluprost. Three patients (2.5%) 
terminated the treatment due to a lack of efficacy, 2 
patients due to conjunctival hyperemia (1.7%), 3 patients 
(2.5%) due to handling issues and preference, 3 patients 
(2.5%) due to tolerability issues (burning, hyperemia, 
stinging, dryness) and 1 patient (0.8%) due to subjective 
malaise.Clinical Ophthalmology 2011:5
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Table 2 Differences in mean iOP between baseline (prior PgA 
therapy) and final visit 12 weeks after changing medication to 
preservative-free tafluprost stratified by reasons for change of 
medication
Reason for changing 
medication
Number  
of patients 
(baseline visit)
δIOP  
(mm Hg)
P-value**
iOP lowering effect  
not sufficient or target  
pressure not achieved
24 -3.9 ,0.001
Ocular signs 31 -1.4 0.009
subjective symptoms 41 -0.1 0.761
Note: **LOCF-analysis, t-test for paired samples.
Abbreviations: δIOP, IOP at final visit minus IOP at baseline; IOP, intraocular 
pressure; PgA, prostaglandin analog.
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Discussion
The results of this non-interventional, open-label, multi-
centre observational study demonstrate that preservative-free 
  tafluprost can achieve good IOP control in patients switched 
from a prior PGA monotherapy due to poor IOP control 
and/or tolerability issues. After change of medication mean 
IOP decreased significantly until final visit by 1.4 mm Hg 
(8.7%). There were two main reasons for switching therapy 
from prior PGA monotherapy to preservative-free   tafluprost: 
  Ocular symptoms and clinical signs like hyperemia accounted 
for 61.0% and a lack of efficacy of prior medication for 20.3% 
of changes of treatment. This may explain why the mean 
(treated) IOP at baseline was relatively low, 16.2 ± 4.3 mm 
Hg. Interestingly, regardless of low mean baseline IOP, lower 
IOP-values were achieved 12 weeks after changing medica-
tion from prior PGA monotherapy in a high proportion of 
patients: IOP was lower compared to baseline IOP in 109 
eyes (46.2%), remained at the same level in 51 eyes (21.6%) 
and was higher in 76 eyes (32.2%). In patients switched due 
to a lack of efficacy of prior PGA monotherapy significant 
lower mean IOP-values were achieved (-3.9 mm Hg ver-
sus treated baseline; P , 0.001). Lower individual IOP’s 
were achieved in 58.2% of all eyes of these patients. These 
findings suggest that it may be worthwhile to consider a 
change of medication to preservative-free tafluprost for 
patients treated with preserved PGAs with insufficient IOP 
response. The efficacy of preservative-free tafluprost was 
compared to other prostaglandins in various studies.9,23–26 
In a study comparing efficacy and safety of tafluprost 
0.0015% and latanoprost 0.005%, Uusitalo et al9 found a 
decrease of mean IOP versus. baseline of -7.1 mm Hg in 
the tafluprost treatment group (-29.1%) compared with Clinical Ophthalmology 2011:5
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-7.7 mm Hg (-32.2%) in the latanoprost treatment group. 
Non-inferiority was shown in this study with ANOVA and 
almost reached with ANCOVA. Compared to these results 
our study design was different: Firstly, patients with prior 
PGA treatment were switched to preservative-free tafluprost 
without any washout-period. Secondly, a high proportion of 
patients were switched to preservative-free tafluprost due to 
tolerability (subjective symptoms and/or clinical signs such 
as hyperemia) and/or efficacy issues. The study design of 
the present study may therefore better reflect the treatment Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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  algorithms in day to day practice and also explain the addi-
tional decrease in mean IOP seen in this study. In a phase I 
study with formulations containing 0.0025 and 0.005% taflu-
prost, IOP was lowered effectively with both concentra-
tions of tafluprost.24 The higher concentration of tafluprost 
provided a significantly greater IOP reduction compared to 
latanoprost for most time-points. However, this study was 
performed in healthy male volunteers over a relatively short 
period of time of 7 days. Another study comparing efficacy 
and tolerability of tafluprost and   travoprost found a difference 
in 12-hour mean IOP of 0.6 mm Hg in favor of travoprost.25 
However, the formulation of tafluprost used in this study 
was not detailed. Due to the double-blind character of this 
study it might be assumed that the preserved-formulation 
of tafluprost was used, which might explain the different 
findings, especially related to the development of clinical 
signs such as hyperemia compared to the present study. The 
presence of the preservative BAK seems to have no influence 
on the efficacy of tafluprost: in a study comparing the effect 
of a BAK-preserved and a preservative-free formulation of 
tafluprost, the formulations did not differ significantly in their 
IOP lowering effect.26 Even a small change in IOP seems 
to be important with respect to visual field and optic nerve 
preservation: every 1 mm Hg was found to be equivalent to an 
increased risk of glaucoma progression of 10% to 19%.3,27
Local tolerability and clinical signs are other important 
factors in patients with chronic diseases such as glaucoma. 
Two aspects are important in this context: firstly, a large body 
of evidence exists showing that the long-term use of topical 
drugs containing BAK as a preservative may induce changes 
in the ocular surface, tear film instability, epithelial apopto-
sis, conjunctival inflammation and loss of goblet cells.14–18 
Secondly, there is evidence that the prevalence of ocular 
surface disorders is high in glaucoma patients: in a study by 
Leung 59% of patients with open-angle glaucoma or ocular 
hypertension reported dry eye symptoms in at least 1 eye.28 
In another study by Erb, dry eye syndrome was diagnosed 
in 52.6% of glaucoma patients.29 In both studies, the occur-
rence of dry eye syndrome increased with the number of 
  preservative- containing antiglaucoma drugs used.
After switching from preserved PGA monotherapy 
to preservative-free tafluprost, subjective symptoms and 
clinical signs such as hyperemia improved significantly 
(P , 0.001) in most patients. Consistent with previous 
reports our results confirm that patients with irritation of the 
ocular surface, subjective symptoms and clinical changes 
of the eye surface, such as hyperemia, may benefit from a 
change of medication to the preservative-free formulation 
of tafluprost.30 During the course of this observational study 
hyperemia which was present in a high proportion of patients 
at baseline decreased significantly: No patient showed a 
severe hyperemia at the end of the study-period. In 87.7% 
of patients with prior PGA-monotherapy treatment no con-
junctival hyperemia was present after 12 weeks. Regarding 
local tolerability of glaucoma medications, clinical studies 
show that a high proportion of glaucoma patients develop 
symptoms like burning and stinging, foreign body sensa-
tion, dry eye and irritation of the ocular surface.   Consistent 
with prior reports19,20 that these symptoms were reported 
significantly less often in patients receiving preservative-
free preparations, subjective symptoms improved until 
final visit in this subset of patients treated with prior PGA 
monotherapy. Preservative-free tafluprost was generally 
well tolerated and safe: 106 patients (89.8%) remained on 
a monotherapy with preservative-free tafluprost after the 
12 weeks of treatment.
This observational study is limited by its open-label 
design. Due to its observational nature, the study did not 
reveal any causal relationships. The observed IOP reduction 
after switching might be ascribed not only to the improve-
ment of subjective symptoms and clinical signs and thus 
a better compliance, but also to the patient population at 
baseline itself. Also, regression to the mean cannot be ruled 
out in the current study design since a control group was 
not used. Further studies with higher numbers of patients 
are necessary to determine what aspects of preservative-free 
therapy with tafluprost account for the observed treatment 
effects.
Conclusion
In this observational study, preservative-free tafluprost 
0.0015% was effective and generally well tolerated in patients 
with prior PGA monotherapy. Preservative-free tafluprost 
provided further IOP reduction in patients with poor IOP 
control and/or poor tolerance of their medication prior to 
tafluprost use. Mean IOP decreased slightly after change 
of medication to preservative-free tafluprost. In patients 
with prior latanoprost monotherapy (n = 68) mean IOP at 
baseline (±SD) was reduced from 16.2 ± 4.6 mm Hg to 
14.8 ± 3.1 mm Hg at final visit (P , 0.001); in patients with 
prior travoprost monotherapy (n = 32) from 16.2 ± 4.3 mm Hg 
to 14.9 ± 3.3 mm Hg (P , 0.05); and in patients with prior 
bimatoprost monotherapy (n = 18) from 16.4 ± 3.5 mm Hg 
to 15.0 ± 3.3 mm Hg (P = 0.252). Change of medication to Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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preservative-free tafluprost may be beneficial especially for 
patients with objective clinical signs and subjective symp-
toms of ocular surface disease: conjunctival hyperemia which 
was present at baseline in 64.4% of patients treated with 
a PGA monotherapy decreased significantly (P , 0.001) 
during the 12 week treatment period and was found in only 
12.3% of patients at final visit. Our data further suggest that 
a change of medical therapy to preservative-free tafluprost 
in patients with prior preserved PGA monotherapy may 
be especially beneficial for patients with subjective ocular 
symptoms and/or clinical signs and also for patients who 
are not responding adequately to a prior PGA monotherapy 
treatment regimen.
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